Biogen Inc
BIIB
Market Cap$32.43B
Close$
$281.88
19.8% upside
Current Fair Value
19.8% upsideUndervalued by 19.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $32.43 Billion |
|---|---|
| Enterprise Value | $37.90 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $8.0 |
| Beta | 0.0 |
| Outstanding Shares | 145,596,895 |
| Avg 30 Day Volume | 1,341,022 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 27.8 |
|---|---|
| PEG | 1960.67 |
| Price to Sales | 3.57 |
| Price to Book Ratio | 2.26 |
| Enterprise Value to Revenue | 3.92 |
| Enterprise Value to EBIT | 20.12 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...